PARP1 and cancer: Because of PARP1’s auto-PARylation activity in the process of the DNA damage response and repair, PARP inhibitors have been used to develop a “synthetic lethality” strategy to treat cancers that carry genetically mutated DSB repair pathways, e.g., BRCAs [71,138,139].